Cargando…

Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?

Detalles Bibliográficos
Autores principales:	Abbas, Tahany, Murad, Walaa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Leibniz Research Centre for Working Environment and Human Factors 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573173/ https://www.ncbi.nlm.nih.gov/pubmed/33088253 http://dx.doi.org/10.17179/excli2020-2745

Ejemplares similares

Concomitant inflammation/metabolism transcriptional regulatory networks in liver disease
por: Abbas, Tahany, et al.
Publicado: (2020)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Lean non-alcoholic fatty liver disease: do not forget diabetes
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2019)

Body Composition and Non-alcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2016)

Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2022)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
por: Rong, Li, et al.
Publicado: (2023)

Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism
por: Emamat, Hadi, et al.
Publicado: (2020)

Eyeing non-alcoholic fatty liver disease: The noninvasive way
por: Gude, Dilip
Publicado: (2011)

Silymarin: An option to treat non-alcoholic fatty liver disease
por: Colica, Carmela, et al.
Publicado: (2017)

Multipronged Approach to Assess Risk Factors for Non-alcoholic Fatty Liver Disease
por: Hidrus, Aizuddin, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19.
por: Bramante, Carolyn T., et al.
Publicado: (2020)

In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kanuri, Giridhar, et al.
Publicado: (2013)

Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Carneros, David, et al.
Publicado: (2020)

Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
por: Parameswaran, Madhangi, et al.
Publicado: (2021)

What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2023)

Noninvasive Imaging for the Evaluation of Non-Alcoholic Fatty Liver Disease Spectrum
por: Liu, Qianjiao, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease, diabetes medications and blood pressure
por: Ilias, Ioannis, et al.
Publicado: (2021)

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
por: Jeong, Seogsong, et al.
Publicado: (2023)

Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
por: Barbier-Torres, Lucía, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies
por: Lu, Li-Yu, et al.
Publicado: (2022)

Fatty Liver Index is a valid predictor of non-alcoholic fatty liver disease (NAFLD) in pregnancy
por: Koralegedara, Iresha Sandamali, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)
por: Roderburg, Christoph, et al.
Publicado: (2023)

Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
por: de Carvalho, Sylene Coutinho Rampche, et al.
Publicado: (2013)

Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar?
por: Longato, Lisa
Publicado: (2013)

Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Saeed, Ali, et al.
Publicado: (2017)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Maciejewska-Markiewicz, Dominika, et al.
Publicado: (2021)

Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences
por: Tripodi, Armando, et al.
Publicado: (2022)

Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
por: Yao, Pengyu, et al.
Publicado: (2022)

Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
por: Moghtadaie, Atie, et al.
Publicado: (2023)

The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Savic, Dragana, et al.
Publicado: (2020)

Comments on Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran
por: Karimi-Sari, H., et al.
Publicado: (2017)

Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease
por: Liu, Dong, et al.
Publicado: (2022)

Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes
por: Loosen, Sven H, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies
por: Jeong, Seogsong, et al.
Publicado: (2022)

Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)
por: Cuthbertson, Daniel J., et al.
Publicado: (2021)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Can Diet Help Non-Obese Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD)?
por: Merchant, Hamid A.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ofh7qt3seu6c9uihb1kpe5kqto